Asia-Pacific markets set to mostly climb as investors await Bank of Korea decision
Twenty47studio | Moment | Getty Images
Asia-Pacific markets were set to mostly climb Thursday as investors look toward the Bank of Korea decision.
Japan's benchmark Nikkei 225 was set to open higher, with the futures contract in Chicago at 38,350 while its counterpart in Osaka last traded at 37,840 against the index's last close of 37,722.4.
Futures tied to Australia's S&P/ASX 200 index stood at 8,430, pointing to a higher open than its last close of 8,396.9.
Hong Kong markets are poised to slip slightly with futures tied to the Hang Seng index at 23,132, compared to the benchmark's last close of 23,258.31.
Investors are expected to keep an eye on the outcome of the Bank of Korea's meeting decision, as well as Asian chip stocks, after Nvidia posted stronger-than-expected earnings and revenue on Wednesday, driven by a 73% year-over-year surge in its data center business.
U.S. futures rose Wednesday night, buoyed by a strong earnings report from artificial intelligence heavyweight Nvidia.
Futures tied to the S&P 500 rose 0.8%, while Nasdaq 100 futures gained 1.2%. Dow Jones Industrial Average futures added 206 points, or 0.5%.
Overnight, the three major stock averages closed lower as investors parsed the latest earnings reports and Federal Reserve meeting minutes.
The S&P 500 slid 0.56% to end at 5,888.55, while the Nasdaq Composite shed 0.51% and settled at 19,100.94. The Dow Jones Industrial Average fell 244.95 points, or 0.58%, and closed at 42,098.70.
— CNBC's Alex Harring, Sarah Min and Pia Singh contributed to this report
The three major indexes concluded Wednesday's session in the red.
The Dow and S&P 500 each finished around 0.6% lower. The Nasdaq Composite ended down 0.5%.
— Alex Harring
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
15 minutes ago
- Bloomberg
Investors Look for Comfortable AI Valuations
Janus Henderson Global Technology and Innovation Team Portfolio Manager Denny Fish says while some AI valuations like Palantir's are speculative, others including Nvidia's are more comfortable for investors. He talks about Janus Henderson's new AI ETF with Caroline Hyde on 'Bloomberg Tech.' (Source: Bloomberg)
Yahoo
18 minutes ago
- Yahoo
Is This the Right Time to Consider Healthcare ETFs?
U.S. healthcare stocks are currently trading at the biggest discount relative to the broader market in 30 years, according to Barrons, presenting a solid opportunity for investors looking for stability and potential growth. The Health Care Select Sector SPDR XLV, which mirrors the sector's performance, has fallen 9.6% over the past year while the broad SPDR S&P 500 ETF Trust SPY climbed about 16%. This has pushed healthcare stocks to trade at a historic valuation discount compared to the broader market. The sector has been struggling due to concerns over political and regulatory uncertainties, including government policies targeting prescription drug prices, tariffs on pharmaceuticals, and reduced funding in health research and Medicaid. The expiry of drug patents and setbacks faced by major companies have contributed to the sector's another sign of waning investor interest, healthcare ETFs have recorded 12 straight months of net outflows through July, totaling $11.5 billion. This represents the largest outflow of any sector, according to State Street Investment Management. Is the Sector Ready for a Rebound? The healthcare sector has gathered momentum with XLV gaining 4.2% over the past week versus a decline of 0.5% for SPY. This signals potential turnaround and came on the back of attractive valuation and growing hedge fund's exposure. Attractive Valuation The sector is currently trading at a forward P/E ratio of around 16, substantially lower than the S&P 500's P/E ratio of about 22 and far below technology's P/E ratio of 30. This discount is the widest seen in three decades, making healthcare stocks some of the most undervalued in the market relative to their earnings potential. Buffett Entry Provides A Major Boost Warren Buffett's Berkshire Hathaway investment in UnitedHealth UNH lifted sentiment, bolstering confidence in managed-care names. In the latest 13F filing, Berkshire Hathaway disclosed that it bought more than 5 million shares in UNH in the second quarter, valued at approximately $1.6 billion. The stock has soared more than 10% in a week (read: Insights Into 13F Filings: ETFs to Invest in Like Billionaires). Other Hedge Funds Increase Exposure Per the latest 13F filings, most hedge funds ramped up exposure to healthcare stocks. Stanley Druckenmiller, renowned investor and head of Duquesne Family Office, has increased his exposure to healthcare stocks as part of a strategic portfolio adjustment during the second quarter. His portfolio, valued at around $3.06 billion, shows a prominent tilt toward innovative healthcare and pharmaceuticals, reflecting his confidence in the sector's growth managers also highlighted exposure to Regeneron REGN and other life sciences names via both equity and calls, showing targeted science-driven bets. Corporate Action Stocks like CVS Health CVS gained on analyst upgrades. Novo Nordisk NVO surged following the FDA approval for a new use of its weight-loss drug (read: NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain). Rotation to Defensive Sectors Amid growing skepticism over lofty tech valuations, investors are shifting toward more stable, defensive sectors. This has helped healthcare stocks attract renewed attention as a safer haven. Healthcare generally outperforms during periods of low growth and high uncertainty, as evidenced in the current macro environment. AI and Technology Integration in Healthcare The emergence of AI-driven healthcare initiatives, such as the Stargate project, promised to revolutionize cancer research and healthcare technologies. This created optimism about innovation-led growth in the sector, attracting investments focused on AI and biotech companies advancing healthcare solutions. Solid Zacks Sector Rank The potential upside to the healthcare sector is confirmed by the Zacks Sector Rank in the top 44%, with about 75% of the industries ranking in the top 41%. This suggests that the momentum built up in the healthcare space lately will likely continue in the coming weeks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report SPDR S&P 500 ETF (SPY): ETF Research Reports Health Care Select Sector SPDR ETF (XLV): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Nvidia's Earnings Could Make Or Break Momentum ETFs
A sudden tumble in the high-flying factor names could be paving the way for a reversal, say Goldman Sachs traders, putting the spotlight on ETFs tied to the factor ahead of NVIDIA Corp.'s (NASDAQ:NVDA) closely followed earnings next week. Nvidia's quarterly results could decide the fate of momentum stocks and the ETFs that track them, after a two-week slide put the high-flying trade under pressure. Nvidia is down more than 4% in the past week. Track its prices live, here. Goldman's High Beta Momentum basket, which bundles together the latest winners in the market and shorts losers, fell 13% from Aug 6 to Aug 19, its fourth drop of over 10% this year, as reported by Bloomberg. Historically, these sharp declines have tended to reverse rapidly from such a point. Goldman Sachs pointed out that in previous instances when the basket declined 10% or more in five days, it recovered during the next week, 80% of the time, with median returns of 4.5% during the next week and over 11% over the subsequent month. The ETF Angle Momentum-based ETFs such as the iShares MSCI USA Momentum Factor ETF (BATS:MTUM) and Invesco Dorsey Wright Momentum ETF (NASDAQ:PDP) offer investors direct exposure to the same high-octane growth stocks that dominate Goldman's basket, the likes of Nvidia, Advanced Micro Devices Inc (NASDAQ:AMD), and Palantir Technologies Inc (NASDAQ:PLTR). That makes the funds especially sensitive to whether Nvidia's earnings next week can revive enthusiasm in AI-related equities or deepen the selloff. ETFs that follow the momentum factor have also experienced uneven returns in 2025, with several abrupt swings related to the AI trade. The latest rout also questions whether these vehicles can be used as tactical trades or not long-term positions. What's Driving The Sell-off Losses in AI leaders such as Palantir, AMD, Super Micro Computer Inc (NASDAQ:SMCI), and even Nvidia, pulled the basket down. These formerly crowded trades now face profit-taking, high valuations, and nervousness about China's competitive squeeze. The Risk To Rebounds Although Goldman's traders point out that momentum has previously rebounded following steep drops, some warn that the factor has been erratic throughout the year. Bloomberg Intelligence's Christopher Cain said that high-momentum stocks have some of the most costly valuations relative to low momentum in history. The last catalyst will depend on Nvidia's earnings next week. As the heaviest weight in the S&P 500 and Nasdaq 100, the chipmaker's report could make or break whether momentum ETFs produce another record rebound — or this is merely the beginning of a more significant correction. Read Next: Photo: Chung-Hao-Lee via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NVIDIA (NVDA): Free Stock Analysis Report This article Nvidia's Earnings Could Make Or Break Momentum ETFs originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
